Terragen (ASX: TGH): Agriculture Biotechnology Firm Advances Commercial Expansion Plans

Key Highlights

• Terragen Holdings (ASX: TGH) shares were trading at AUD 0.020 on 29 July 2026 after the company released its latest quarterly activities report.
• The company secured conditional supply agreements linked to its Terragen Probiotic® for Ruminants product across major livestock operations.
• A large-scale beef cattle trial involving Mort & Co and Meat & Livestock Australia is underway, with external funding support of up to AUD 2.8 million.
• Terragen is expanding commercial opportunities through livestock health products, global market access initiatives, and agricultural innovation programs.

Terragen Holdings Limited (ASX: TGH) shares were trading at AUD 0.020 on 29 July 2026 as investors reviewed the company’s latest quarterly activities report covering the period ended 30 June 2026. The Australian biological agriculture company highlighted progress across commercial agreements, livestock trials, product development initiatives, and market expansion activities.

The latest update focused on Terragen’s efforts to move its biological agriculture solutions from development and trial phases toward broader commercial adoption, particularly within the livestock sector.

Share Price Performance Reflects Market Assessment of Commercial Progress

Terragen’s share price remained at AUD 0.020 following the company’s quarterly report, with investors assessing developments around its probiotic livestock products and potential commercial rollout.

The company operates in the agricultural biotechnology sector, where market attention is often influenced by product validation, customer adoption, regulatory developments, and the ability to convert research initiatives into recurring revenue streams.

Terragen’s latest report provided several operational milestones, including conditional sales contracts, progress on major livestock trials, and expansion of its agricultural technology pipeline.

Conditional Sales Agreements Create Commercial Pathway

A key development during the quarter was Terragen securing conditional sales contracts for its livestock-focused products.

The company announced a commercial supply agreement with Ramps Ridge Pty Ltd, operating as Ravensworth Feedlot in New South Wales, for the supply of Terragen Probiotic® for Ruminants (TPR) and Great Land Plus® (GLP).

The agreement represents one of Terragen’s first large-scale commercial deployments of TPR within major livestock operations.

Under the agreement, once conditions are satisfied, a minimum order of 360,000 doses must be placed by the later of 1 December 2026 or 90 days after completion of required conditions.

The product is intended for use across livestock operations of up to 40,000 head of cattle per day, with performance indicators reviewed every six months.

The agreement has an initial term of 12 months from the first delivery date, which Terragen expects to occur in late calendar year 2026.

Mort & Co Trial Supports Future Livestock Expansion

Another important component of Terragen’s quarterly update was the commencement of a large-scale feedlot performance and eating-quality trial with Mort & Co.

The trial is supported by Meat & Livestock Australia Donor Company and Mort & Co and involves up to 10,600 beef cattle.

The objective is to evaluate the impact of Terragen Probiotic® for Ruminants within a commercial feedlot environment.

Terragen stated that successful trial outcomes could support increased adoption of TPR and potentially result in higher sales during FY27 compared with FY26 levels.

The company has entered into a supply agreement with Mort & Co, which remains subject to successful completion of the trial.

The outcome of this program is expected to be a key factor in determining future commercial opportunities for the product.

Focus on Biological Agriculture Solutions

Terragen’s business strategy centres on developing biological solutions designed to support agricultural productivity.

The company’s product portfolio includes microbial-based technologies aimed at improving livestock and agricultural outcomes.

The latest update highlighted continued work on expanding market opportunities for Terragen Probiotic® and developing additional solutions, including research into nitrogen-use efficiency technologies.

The company is also progressing its global market access activities as it seeks to expand opportunities beyond the Australian agricultural market.

Companion Animal Development Expands Product Applications

Terragen reported continued development work involving Terragen Probiotic® for companion animals.

The initiative represents an opportunity to broaden the company’s biological technology applications beyond livestock agriculture.

While livestock remains the primary commercial focus, expanding into additional animal health categories could provide further product opportunities as the company develops its technology platform.

Winter Crop Trials Underway Across Australia

The company also provided an update on its winter crop trial program, which is underway across southern Australia.

Agricultural trials are an important part of Terragen’s approach to demonstrating product effectiveness under different environmental and farming conditions.

The company continues to evaluate opportunities where biological solutions may support agricultural productivity and resource efficiency.

Nutrien Agreement Supports Distribution Opportunity

Terragen highlighted its national supply agreement with Nutrien Ag Solutions Australia as another step in strengthening its commercial network.

The agreement provides an opportunity to increase access to agricultural customers through an established industry distribution channel.

Distribution partnerships can play an important role in scaling agricultural technology products by improving market reach and supporting customer engagement.

Strengthening Innovation Capability

During the quarter, Terragen appointed a Manager, Innovation & Adoption as part of its continued focus on commercialising agricultural technology.

The appointment is aimed at supporting the adoption of Terragen products and improving engagement with industry participants.

As the company advances its commercial activities, execution across product adoption, customer relationships, and market development will remain important areas of focus.

Investor Focus Ahead

Investors are expected to closely monitor the results of the Mort & Co trial, progress toward commercial supply commencement with Ravensworth Feedlot, and the pace of product adoption.

The company’s future performance will depend on converting conditional agreements into ongoing commercial sales and demonstrating repeat demand for its biological agriculture solutions.

Further updates regarding supply agreements, trial outcomes, and market expansion initiatives are likely to remain important factors influencing investor sentiment.

Conclusion

Terragen (ASX: TGH) continues to progress its commercialisation strategy within the biological agriculture sector, with its latest quarterly report highlighting conditional livestock supply agreements, major field trials, and expansion initiatives. While the share price remained around AUD 0.020 after the update, market attention is focused on whether Terragen can successfully transition its technology into broader commercial adoption. The outcomes of livestock trials, customer agreements, and product expansion initiatives will be important in shaping the company’s future development.